Mod­er­na cal­i­brates fi­nal Covid-19 vac­cine ef­fi­ca­cy at 94.1% — and to­day it's gun­ning for the EUA

Near­ly a year ago, as the coro­n­avirus emerged in Chi­na, the NIH and four ma­jor com­pa­nies bet on an un­proven ge­net­ic tech­nol­o­gy as the best tool for de­vel­op­ing a vac­cine to stem the out­break. To­day, a sec­ond such vac­cine is head­ing to the FDA.

Mod­er­na said Mon­day that they will re­quest an emer­gency use au­tho­riza­tion from the FDA af­ter a fi­nal analy­sis showed their mR­NA vac­cine was 94.1% ef­fec­tive at pre­vent­ing symp­to­matic Covid-19. The da­ta con­firm the re­sults from an in­ter­im analy­sis and match­es ef­fi­ca­cy Pfiz­er and BioN­Tech showed in a Phase III study, set­ting the biotech up to po­ten­tial­ly nab one of the first two Covid-19 vac­cine OKs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER